Literature DB >> 28338112

PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population.

Juozas Kupcinskas1, Irena Valantiene1, Greta Varkalaitė2, Ruta Steponaitiene2, Jurgita Skieceviciene2, Jolanta Sumskiene3, Vitalija Petrenkiene3, Jurate Kondrackiene3, Gediminas Kiudelis1, Frank Lammert4, Limas Kupcinskas5.   

Abstract

BACKGROUND AND AIMS: Genome-wide association studies have revealed an association between the risk of developing liver fibrosis or cirrhosis and the single nucleotide polymorphisms (SNPs) of the PNPLA3, RNF7, MERTK and PCSK7 genes. We aimed to validate these results in an Eastern European population.
METHODS: We evaluated the associations between the PNPLA3 (rs738409), RNF7 (rs16851720), MERTK (rs4374383) and PCSK7 (rs236918) variants and liver fibrosis and cirrhosis in a series of consecutive patients recruited at the Department of Gastroenterology, Lithuanian University of Health Sciences Hospital, during the period 2012-2015. The study included 317 individuals with liver cirrhosis, 154 individuals with liver fibrosis, and 498 controls. The studied SNPs were determined using RT-PCR TaqMan assays.
RESULTS: MERTK and PCSK7 SNPs were not associated with liver fibrosis or cirrhosis. The PNPLA3 SNP rs738409 was associated with a higher risk of developing liver fibrosis (aOR: 1.65, P=0.001) and cirrhosis (aOR: 1.92, P=5.57*10-7). PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models. RNF7 rs16851720 was associated with liver cirrhosis comparing CC vs. AA + CA genotypes (aOR: 0.26, P=0.020).
CONCLUSION: Our study showed that PNPLA3 rs738409 and RNF7 rs16851720 confer an increased risk of developing liver fibrosis and cirrhosis in this Eastern European population, while the MERTK and PCSK7 SNPs are not associated with these conditions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28338112     DOI: 10.15403/jgld.2014.1121.261.pnp

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  6 in total

1.  Identifying and Exploring the Candidate Susceptibility Genes of Cirrhosis Using the Multi-Tissue Transcriptome-Wide Association Study.

Authors:  Xiao-Bo Zhu; Yu-Qing Hou; Xiang-Yu Ye; Yi-Xin Zou; Xue-Shan Xia; Sheng Yang; Peng Huang; Rong-Bin Yu
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

Review 2.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

3.  Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients.

Authors:  Juozas Grigas; Maria Montoya; Evelina Simkute; Marius Buitkus; Ruta Zagrabskaite; Arnoldas Pautienius; Dainius Razukevicius; Laimas Virginijus Jonaitis; Gediminas Kiudelis; Jurgita Skieceviciene; Ruta Vaiciuniene; Asta Stankuviene; Inga Arune Bumblyte; Juozas Kupcinskas; Arunas Stankevicius
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

4.  MiR-34a promotes fibrosis of hepatic stellate cells via the TGF-β pathway.

Authors:  Peng Zhao; Xiaoyan Wu; Jie Zhang; Haixia Wang; Linlin Yao
Journal:  Ann Transl Med       Date:  2021-10

5.  PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.

Authors:  Bisma Rauff; Ali Amar; Badr Alzahrani; Shafiq A Chudhary; Bilal Nasir; Saqib Mahmood; Munir Ahmad Bhinder; Muhammad Faheem
Journal:  BMC Gastroenterol       Date:  2022-08-26       Impact factor: 2.847

Review 6.  Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases.

Authors:  Hongjiao Xiang; Zecheng Wu; Junmin Wang; Tao Wu
Journal:  J Cancer       Date:  2021-08-13       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.